Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke.

Bennett D, Yan B.

J Clin Neurosci. 2013 Jun;20(6):767-70. doi: 10.1016/j.jocn.2012.09.027. Epub 2013 Apr 22. Review.

PMID:
23618682
2.

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.

Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS.

Lancet. 2010 Oct 16;376(9749):1312-9. doi: 10.1016/S0140-6736(10)61273-1.

3.

The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.

Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, Steg PG, Montalescot G, Bhakta N, Hacke W, Flather MD, Mak KH, Cacoub P, Creager MA, Berger PB, Steinhubl SR, Murugesan G, Mehta SR, Kottke-Marchant K, Lincoff AM, Topol EJ; CHARISMA Investigators.

Eur Heart J. 2012 Sep;33(17):2143-50. Epub 2012 Mar 26.

PMID:
22450429
4.

Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.

Subraja K, Dkhar SA, Priyadharsini R, Ravindra BK, Shewade DG, Satheesh S, Sridhar MG, Narayan SK, Adithan C.

Eur J Clin Pharmacol. 2013 Mar;69(3):415-22. doi: 10.1007/s00228-012-1381-8. Epub 2012 Sep 6.

PMID:
22955794
5.

CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.

Jia DM, Chen ZB, Zhang MJ, Yang WJ, Jin JL, Xia YQ, Zhang CL, Shao Y, Chen C, Xu Y.

Stroke. 2013 Jun;44(6):1717-9. doi: 10.1161/STROKEAHA.113.000823. Epub 2013 May 2.

6.

Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.

Zhang L, Chen Y, Jin Y, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Li X, Li Y, Zhang Y, Lu C, Yin T.

Thromb Res. 2013 Jul;132(1):81-7. doi: 10.1016/j.thromres.2013.05.006. Epub 2013 May 29.

PMID:
23726091
7.

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A.

Eur Heart J. 2011 Jul;32(13):1605-13. doi: 10.1093/eurheartj/ehr155. Epub 2011 Apr 28.

PMID:
21527445
8.

Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.

Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W.

Arch Cardiovasc Dis. 2013 Oct;106(10):517-27. doi: 10.1016/j.acvd.2013.06.055. Epub 2013 Sep 27. Review.

9.

Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.

Qiu LN, Sun Y, Wang L, Han RF, Xia XS, Liu J, Li X.

Eur J Pharmacol. 2015 Jan 15;747:29-35. doi: 10.1016/j.ejphar.2014.11.037. Epub 2014 Dec 6.

PMID:
25489921
10.

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.

Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC; PLATO investigators.

Lancet. 2010 Oct 16;376(9749):1320-8. doi: 10.1016/S0140-6736(10)61274-3.

PMID:
20801498
11.

The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.

Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML.

JACC Cardiovasc Interv. 2008 Dec;1(6):620-7. doi: 10.1016/j.jcin.2008.09.008.

12.
13.

Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.

Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B.

J Thromb Haemost. 2012 Apr;10(4):529-42. doi: 10.1111/j.1538-7836.2012.04639.x.

14.
16.

CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.

Yang J, Zhao HD, Tan J, Ding YL, Gu ZQ, Zou JJ.

Pharmazie. 2013 Mar;68(3):183-6.

PMID:
23556336
17.

Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.

Jin B, Ni HC, Shen W, Li J, Shi HM, Li Y.

Mol Biol Rep. 2011 Mar;38(3):1697-702. doi: 10.1007/s11033-010-0282-0. Epub 2010 Sep 16.

PMID:
20845077
18.

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.

Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP.

JAMA. 2011 Dec 28;306(24):2704-14. doi: 10.1001/jama.2011.1880. Review.

PMID:
22203539
19.

Progress of antiplatelet pharmacogenomics.

Oestreich JH.

Curr Drug Targets. 2011 Nov;12(12):1848-58. Review.

PMID:
21718233
20.

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.

Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A.

Circulation. 2010 Feb 2;121(4):512-8. doi: 10.1161/CIRCULATIONAHA.109.885194. Epub 2010 Jan 18.

Supplemental Content

Support Center